Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
October 6, 2015 7:50 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening.
U.S. Preventive Services Task Force Webcast and Conference Call Details
  Date:  Tuesday, Oct. 6, 2015 Time: 9 a.m. ET, 8 a.m. CT... MoreCologuard® Included as Alternative Screening Test under Draft USPSTF Guidelines
October 5, 2015 8:21 PM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for colorectal cancer screening starting at age 50 and continuing until age 75.... More
